Eupraxia Pharmaceuticals (EPRX) Enterprise Value (2024 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Enterprise Value for 5 consecutive years, with -$140.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 383.98% year-over-year to -$140.5 million; the TTM figure through Mar 2026 stood at -$140.5 million (down 383.98% YoY), while the FY2025 annual figure was -$82.2 million, down 136.99% from the prior year.
• Enterprise Value declined to -$140.5 million in Q1 2026 per EPRX's latest filing, from -$82.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$8.0 million in Q4 2022 and bottomed at -$140.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$45.4 million across 5 years, with a median of -$29.0 million in 2025.
• On a YoY basis, Enterprise Value climbed as much as 22.28% in 2025 and fell as far as 787.32% in 2025.
• Eupraxia Pharmaceuticals' Enterprise Value stood at -$8.0 million in 2022, then tumbled by 157.96% to -$20.7 million in 2023, then slumped by 67.75% to -$34.7 million in 2024, then slumped by 136.99% to -$82.2 million in 2025, then sank by 70.98% to -$140.5 million in 2026.
• Business Quant data shows EPRX's Enterprise Value at -$140.5 million in Q1 2026, -$82.2 million in Q4 2025, and -$90.5 million in Q3 2025.